The AstraZeneca company, in conjunction with the American heart Institute of St. Luke the beginning of the international randomized phase III trial conducted to assess scope of application dapagliflozin patients admitted with a diagnosis of COVID-19 and a high risk of developing serious complications, such as insufficiency of the function of internal organs.
The purpose of the study DARE-19: assess whether the drug drugs, which is an inhibitor of sodium-glucose cotransporter 2nd type (НГЛТ2), to reduce the risk associated with COVID-19 diseases, critical complications and death in patients with factors of cardiovascular (CV) and metabolic risk as well as risk factors for chronic kidney disease. The primary endpoint of efficacy in the study was the time to death from any cause or the occurrence/worsening of organ dysfunction during the 30 days follow-up.
Concomitant diseases of the heart and kidneys, and metabolic disorders in patients suffering from COVID-19, led to adverse clinical outcomes and death. The research design builds on existing data about the effects of the drug drugs in patients suffering from heart failure with reduced ejection fraction (Snpv), chronic kidney disease (CKD) or diabetes mellitus 2 type (DM2).
Recruitment of patients for participation in the study DARE-19 opened in the United States and several European countries, where there is a high incidence of COVID-19; for participation in the study is expected to recruit about 900 patients.